STYLE SHEET
GLOBAL CSS
COLORS
ANIMATIONS
MEDIA QUERY
SPACING SYSTEM

Why only for healthcare professionals?

The content on these information pages is directed solely at you if you are a doctor, nurse, or pharmacist, as it concerns treatment with prescription medicines.

Please confirm that you are a healthcare professional (healthcare assistant, nurse, doctor, psychologist, or other licensed healthcare professional).

Back to main page

Confirm and continue

News
January 16, 2026

Yazen provides Christmas buffet strategy

Yazen makes the festive period easier for people on weight loss injections with a Christmas buffet strategy to instill confidence not fear!

Festive christmas meal
For the estimated 1.5 million people in the UK using GLP-1 or GIP medications, the festive period can present a unique challenge: managing holiday celebrations while continuing their treatment. Yazen is offering expert guidance to help patients navigate the season with confidence.

Yazen psychologist Sofie Franke explains the pressure of "social imitation" during gatherings, where focus shifts to social connection, potentially weakening the brain's ability to recognise satiety signals. To counter this, she offers three practical strategies: set one small, manageable intention; build in brief pause moments to check in with feelings; and prepare simple boundary phrases like "I’m good for now, thanks."

Dr. Martin Carlsson, Yazen’s chief physician, stresses that obesity is a chronic disease requiring continuous treatment. His advice for the holidays focuses on medication and behaviour: mind portions and timing to prevent nausea and discomfort, and crucially, maintain the regular medication schedule for stable appetite control. This integrated approach is echoed by Yazen patient, Annest Dalby, who shared that having her dedicated care team's support has allowed her to focus on enjoying family time instead of fixating on food.

Link to Crave article 

More news

Yazen achieved record-breaking growth in 2025, doubling its revenue.

In 2025, Yazen's revenue surged 87% to nearly €29.4 million, with gross profits doubling to €16.5 million. Now treating over 37,000 active patients across seven countries, the company is eyeing further expansion into two more markets in 2026. Despite an EBITDA of –€5.7 million due to heavy growth investment, Yazen remains a leader in European obesity care.

Yazen presents new data on digital obesity care at NOM 2026

Yazen presents an oral scientific abstract at the Nordic Obesity Meeting (NOM26), highlighting high-volume patient–caregiver interactions in a fully digital obesity care model.

Yazen Highly Commended in the HTN Now 2025/26 Awards

Yazen’s work powering digital patient transformation for sustainable weight care is recognised by the HTN Now 2025/26 Awards in the category of Digital Patient Transformation.